Cantargia – executive interview

Published on 24 June 2022

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are non-small cell lung cancer and pancreatic cancer. CAN10, the company’s second lead asset, is being developed for autoimmune diseases. In this video, Cantargia’s chief executive officer Göran Forsberg provides an update on the recently announced rights issue and key clinical highlights.

Share this with friends and colleagues